Icon

LEVOXYL (nda021301)- (0.025MG,0.025MG,0.05MG,0.05MG,0.075MG,0.075MG,0.088MG,0.088MG,0.1MG,0.1MG,0.112MG,0.112MG,0.125MG,0.125MG,0.137MG,0.137MG,0.15MG,0.15MG,0.175MG,0.175MG,0.2MG,0.2MG,0.3MG)

LEVOTHYROXINE SODIUM KING PHARMS
0.025MG,0.025MG,0.05MG,0.05MG,0.075MG,0.075MG,0.088MG,0.088MG,0.1MG,0.1MG,0.112MG,0.112MG,0.125MG,0.125MG,0.137MG,0.137MG,0.15MG,0.15MG,0.175MG,0.175MG,0.2MG,0.2MG,0.3MG
Yes Yes
2023-Oct-02 Expired
None None
None No
LEVOXYL is L-thyroxine (T4) indicated in pediatric and adult patients for:  Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.  Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer.
0 0 0
Total Other Developers 18
Drugs with Suitability No
0.025MG ** ** Up - -
0.05MG ** ** Up - -
0.075MG ** ** Up - -
0.088MG ** ** Up - -
0.1MG ** ** Up - -
0.112MG ** ** Up - -
0.125MG ** ** Up - -
0.137MG ** ** Up - -
0.15MG ** ** Up - -
0.175MG ** ** Up - -
0.2MG ** ** Up - -
0.3MG ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.